Would only consider doing this if, as part of the transition,...

Would only consider doing this if, as part of the transition, Poppy refinances us via her Westpac connections

But seriously, if I were in Mary-Beth Brinson’s shoes right now I’d be sitting down for individual sessions with neuroscience business unit directors from companies with offices in Australia (for starters) like Janssen/J&J Medical, Takeda, Shire, Eli Lilly, along with their digital innovation leaders, and then extending out to companies in the US like Corium and Supernus, and pitching this tech as a diagnostic complement to their existing ADHD pharma lines. Pitched correctly and to the right people I don’t see why they would not be interested to at least discuss and assess. My guess is that this is presently not occurring.